Literature DB >> 3081444

Differences in susceptibility of inbred mice to Bacillus anthracis.

S L Welkos, T J Keener, P H Gibbs.   

Abstract

Animal species differ in their resistance both to infection by Bacillus anthracis and to anthrax toxin. A mouse model was developed to study the basis of the host differences and the pathogenesis of infection. When mice were infected with the virulent B. anthracis strain Vollum 1B, low 50% lethal dose (LD50) values (5 to 30 spores) were found for all 10 strains of inbred mice tested. However, analysis of time-to-death data revealed significant differences among the strains, which could be divided into three groups: most susceptible (A/J and DBA/2J); least susceptible (CBA/J, BALB/cJ, and C57BR/cdJ); and intermediate (the remaining five strains). In contrast, the mice were distinctly susceptible or resistant to lethal infection by the toxigenic, nonencapsulated Sterne vaccine strain. The LD50 for the susceptible A/J and DBA/2J mice was approximately 10(3) spores of the Sterne strain, whereas the remaining eight relatively resistant strains were killed only by 10(6) or more spores. F1 hybrid and backcross studies suggested that resistance to the Sterne strain is determined by a single dominant gene or gene complex. Mice lethally infected with B. anthracis showed an acute course of infection, characterized by extensive gelatinous edema and large concentrations of bacilli in the blood and organs (e.g., 10(9) CFU/g of spleen). The susceptibility of A/J and CBA/J mice to intravenously injected anthrax toxin components appeared to differ from their susceptibility to infection. The toxin LD50 values for both strains were similar. However, CBA/J mice died sooner than did A/J mice, with mean time to death of 0.9 and 3.7 days, respectively, in mice given 4 LD50 of toxin. The mouse model appears to be useful in studies on host resistance to anthrax and on the pathogenesis of the infection.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3081444      PMCID: PMC260968          DOI: 10.1128/iai.51.3.795-800.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  THE CHEMICAL BASIS OF THE VIRULENCE OF BACILLUS ANTHRACIS. IX. ITS AGGRESSINS AND THEIR MODE OF ACTION.

Authors:  J KEPPIE; P W HARRIS-SMITH; H SMITH
Journal:  Br J Exp Pathol       Date:  1963-08

2.  EFFECT OF EGG YOLK AND PHOSPHATIDES ON ANTHRAX INFECTION OF RATS AND GUINEA PIGS.

Authors:  W D SAWYER; R W KUEHNE; W S GOCHENOUR
Journal:  Proc Soc Exp Biol Med       Date:  1965-01

3.  Production of toxin in vitro by Bacillus anthracis and its spearation into two components.

Authors:  C B THORNE; D M MOLNAR; R E STRANGE
Journal:  J Bacteriol       Date:  1960-03       Impact factor: 3.490

4.  Immunological studies of anthrox. II. Levels of immunity against Bacillus anthracis obtained with protective antigen and live vaccine.

Authors:  F KLEIN; I A DEARMON; R E LINCOLN; B G MAHLANDT; A L FERNELIUS
Journal:  J Immunol       Date:  1962-01       Impact factor: 5.422

5.  Value of field data for extrapolation in anthrax.

Authors:  R E Lincoln; J S Walker; F Klein; A J Rosenwald; W I Jones
Journal:  Fed Proc       Date:  1967-09

6.  Anthrax toxic complex.

Authors:  H Smith; H B Stoner
Journal:  Fed Proc       Date:  1967-09

7.  Germination of B. anthracis spores in the peritoneal cavity of rats and establishment of anthrax.

Authors:  Y Hachisuka
Journal:  Jpn J Microbiol       Date:  1969-06

8.  Genetics of natural resistance to salmonellae in mice.

Authors:  C E Hormaeche
Journal:  Immunology       Date:  1979-06       Impact factor: 7.397

9.  DUAL NATURE OF RESISTANCE MECHANISMS AS REVEALED BY STUDIES OF ANTHRAX SEPTICEMIA.

Authors:  F KLEIN; B W HAINES; B G MAHLANDT; I A DEARMON; R E LINCOLN
Journal:  J Bacteriol       Date:  1963-05       Impact factor: 3.490

10.  Effects of anthrax toxin components on human neutrophils.

Authors:  J O'Brien; A Friedlander; T Dreier; J Ezzell; S Leppla
Journal:  Infect Immun       Date:  1985-01       Impact factor: 3.441

View more
  128 in total

1.  Mailborne transmission of anthrax: Modeling and implications.

Authors:  Glenn F Webb; Martin J Blaser
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-14       Impact factor: 11.205

Review 2.  New insights into the biological effects of anthrax toxins: linking cellular to organismal responses.

Authors:  Annabel Guichard; Victor Nizet; Ethan Bier
Journal:  Microbes Infect       Date:  2011-09-08       Impact factor: 2.700

3.  Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo.

Authors:  Miroslav S Sarac; Juan R Peinado; Stephen H Leppla; Iris Lindberg
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

4.  Anthrax toxin targeting of myeloid cells through the CMG2 receptor is essential for establishment of Bacillus anthracis infections in mice.

Authors:  Shihui Liu; Sharmina Miller-Randolph; Devorah Crown; Mahtab Moayeri; Inka Sastalla; Shu Okugawa; Stephen H Leppla
Journal:  Cell Host Microbe       Date:  2010-11-18       Impact factor: 21.023

5.  Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax.

Authors:  E D Williamson; I Hodgson; N J Walker; A W Topping; M G Duchars; J M Mott; J Estep; C Lebutt; H C Flick-Smith; H E Jones; H Li; C P Quinn
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

6.  Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge.

Authors:  Manuel Osorio; Yanping Wu; Sunil Singh; Tod J Merkel; Siba Bhattacharyya; Milan S Blake; Dennis J Kopecko
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

7.  Antimicrobial effects of interferon-inducible CXC chemokines against Bacillus anthracis spores and bacilli.

Authors:  Matthew A Crawford; Yinghua Zhu; Candace S Green; Marie D Burdick; Patrick Sanz; Farhang Alem; Alison D O'Brien; Borna Mehrad; Robert M Strieter; Molly A Hughes
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

8.  Bacillus anthracis has two independent bottlenecks that are dependent on the portal of entry in an intranasal model of inhalational infection.

Authors:  David E Lowe; Stephen M C Ernst; Christine Zito; Jason Ya; Ian J Glomski
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

9.  Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.

Authors:  Paul G Ambrose; Alan Forrest; William A Craig; Chistopher M Rubino; Sujata M Bhavnani; George L Drusano; Henry S Heine
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

10.  BslA, the S-layer adhesin of B. anthracis, is a virulence factor for anthrax pathogenesis.

Authors:  Justin Kern; Olaf Schneewind
Journal:  Mol Microbiol       Date:  2009-11-10       Impact factor: 3.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.